Harren Jhoti co-founded Astex in 1999 and was chief scientific officer until November 2007 when he was appointed chief executive. He also served as president and member of the Board of Directors of Astex Pharmaceuticals Inc., following the merger of Astex with SuperGen Inc., (subsequently renamed Astex Pharmaceuticals Inc.) in July 2011.
Dr. Jhoti was elected a Fellow of the Royal Society of Biology in 2017, a Fellow of the Royal Society of Chemistry in 2016 and of the Academy of Medical Sciences in 2015. He was awarded the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery by the European Federation for Medicinal Chemistry in 2012 and was also named by the Royal Society of Chemistry as “Chemistry World Entrepreneur of the Year” for 2007. In January 2018 he was honoured with a Lifetime Achievement Award from the UK BioIndustry Association (BIA).
He has published widely including in leading journals such as Nature and Science and has also been featured in TIME magazine after being named by the World Economic Forum a Technology Pioneer in 2005. Dr. Jhoti previously served on the board of the BIA, the UK BioIndustry Association and currently consults for Life Science Venture Capital firms. Before founding Astex in 1999, he was head of Structural Biology and Bioinformatics at GlaxoWellcome in the United Kingdom (1991-1999). Prior to Glaxo, Dr. Jhoti was a post-doctoral scientist at Oxford University.
He received a B.Sc. (Hons) in Biochemistry in 1985 and a Ph.D. in Protein Crystallography from the University of London in 1989.